PExA’s lung cancer research instrument featured by Aftonbladet, Sweden’s largest news site
Aftonbladet, Sweden’s largest news site, is the latest in a series of major Swedish media outlets to highlight the research conducted by Professor Sandra Lindstedt and her research group at Lund University, where PExA’s patented research instrument is being used. On January 4, the newspaper published an in-depth article describing how Professor Lindstedt and her research group use the instrument to analyse exhaled air in an effort to detect lung cancer at an early stage.
The article, titled “Lung cancer can be detected early – through exhalation”, notes that Professor Lindstedt and her research team have received SEK 27 million from the Swedish Cancer Society to further develop the method — a fact previously communicated by PExA.
Aftonbladet is one of Sweden’s leading news outlets, with a digital reach exceeding 67 percent of the population, according to ORVESTO Internet, and is the largest across all channels (print, online and mobile).
Using the PExA instrument, Professor Lindstedt and her research team have identified approximately ten markers in exhaled air that can be linked to cancer. By analyzing the particle material collected with PExA, the researchers have also been able to distinguish between different types of lung cancer.
“It surprised us a little, but it is very clear,” Professor Lindstedt told Aftonbladet.
Traditional lung cancer tests are associated with extensive procedures, and in order for tumours to be detected using conventional CT imaging, they often need to have grown to a considerable size. By instead analyzing particles collected from exhaled air, Professor Lindstedt explains that it may be possible to obtain information associated with lung cancer at an earlier stage. The long-term ambition is for the method to potentially be developed into a screening tool for use in hospitals and primary care settings.
“If we can identify more patients at an earlier stage, much is gained. With a standardised method based on analysis of exhaled air, it could be possible to detect very small tumours,” Professor Lindstedt said in the interview with Aftonbladet.
“Today, there are no screening programmes capable of detecting lung cancer at very early stages, despite the fact that early detection fundamentally changes treatment options. That is why this research — and the technology that enables it — represents an important step towards the diagnostics of the future,” says Tomas Gustafsson, CEO of PExA AB.
Read the article here (in Swedish):
https://www.aftonbladet.se/halsa/a/25MMra/lungcancer-kan-upptackas-tidigt-via-utandningen
For further information, please contact:
Tomas Gustafsson, CEO, info@pexa.se
About PExA AB:
PExA AB (556956-9246) has developed the PExA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA’s technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 50 scientific publications, which serve as reference material for PExA’s method. The company’s long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.
PExA’s B share is listed on the Spotlight Stock Market.